UCB announced today that Keppra XR offers convenient dosing for people with epilepsy. Keppra XR was approved by the U.S. Food and Drug Administration (FDA) in September 2008 for use as an add-on to other antiepileptic treatments for people with partial-onset seizures who are 16 years of age and older.
While many people with epilepsy are successfully treated with one or more of the currently available antiepileptic drugs, a significant percentage still live with uncontrolled seizures or intolerable side effects.
A recent online survey of 451 people living with epilepsy showed that almost half missed at least one dose of their epilepsy medication in the last month, and 37 percent who missed a dose reported having a breakthrough seizure. More than 80 percent of these people missed a dose of an antiepileptic drug (AED) that was taken multiple times daily and the most common reason reported for having missed a dose was forgetfulness. The survey was conducted by UCB.
Keppra XR offers once-daily dosing and is made specifically for epilepsy. Keppra XR is the only extended-release formulation of levetiracetam, and there is no generic version available.
UCB - The Epilepsy Company
"The launch of Keppra XR is the first of many upcoming milestones for UCB's epilepsy franchise," said Rich Denness, vice president & general manager, CNS, UCB. "At UCB, we are committed to developing innovative treatments for epilepsy and improving the lives of people and their families living with this condition."
The immediate release tablet form of Keppra (levetiracetam) was first approved by the FDA in 1999 as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. Since then, Keppra has become a leading antiepileptic drug in the U.S.
In addition, a new epilepsy therapy, Vimpat (lacosamide) was approved by the FDA in late October 2008 and will be commercially available in early 2009. Vimpat is approved for use as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are 17 years and older.
About the Survey
The online survey was conducted by UCB. Email invitations were sent to 4,000 randomly selected email addresses from a database. Survey responses were limited to 500 complete responses in order to achieve a minimum 95 percent confidence interval, 5 percent margin of error and 50 percent proportion. The 500 responses were collected and validated, resulting in 451 usable respondents.
- Online survey shows people living with epilepsy often miss a dose of their antiepileptic drug
-- UCB continues to build on the company's commitment to patients living with epilepsy through the launch of Keppra XR (levetiracetam) extended-release tablets
-- Keppra XR is one of many upcoming milestones in the UCB Epilepsy Franchise